Rhelion unit expands psilocybin supply deal for Italian clinical trial

Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) announced that its wholly owned subsidiary, Filament Health Corp., has expanded a supply and licence agreement with the University G. d'Annunzio of Chieti-Pescara in Italy to provide additional quantities of its botanical psilocybin drug candidate, PEX010, for a clinical trial targeting treatment-resistant depression.

The trial, called TEMPO, was authorized under the European Union Clinical Trials Regulation with EU CT number 2025-523346-27-00. During the regulatory review process, the number of trial participants was increased, prompting the expansion of the supply agreement to provide additional PEX010 25 mg capsules. Filament also provides regulatory support for the trial and the release of PEX010 for use within the European Union.

The University is the sponsor of the trial, which is coordinated with the Istituto Superiore di Sanità, the Italian National Institute of Health. Filament is not the trial sponsor and is not responsible for its conduct. The trial has been reported in Italian press as the first clinical trial of psilocybin conducted in Italy.

PEX010 is a standardized, GMP-manufactured botanical psilocybin product available in 1, 5, and 25 mg doses, with a 0.5 mg dose planned. Rhelion completed its acquisition of Filament Health Corp. on April 30, 2026, gaining access to Filament's lead drug candidate and a portfolio of 78 issued patents across 13 patent families. According to the company, PEX010 currently supports more than 80 academic and philanthropic research studies worldwide.

You May Also Be Interested In

• Irenic Capital opposes Independence Realty's Centerspace deal - Bloomberg
• Broadridge and Korea Securities Depository sign proxy voting MOU
• Centuri Appoints Michael Christy as EVP, Group Development Officer